

## Tumor Antigen by Immunoassay CA 15-3/CA 27.29 (86300) – NCD 190.29

### Indications:

Multiple tumor markers are available for monitoring the response of certain malignancies to therapy and assessing whether a residual tumor exists post-surgical therapy. CA 15-3 is often medically necessary to aid in the management of patients with breast cancer. Serial testing must be used in conjunction with other clinical methods for monitoring breast cancer. For monitoring, if medically necessary, use consistently either CA 15-3 or CA 27.29, not both. CA 27.29 is equivalent to CA 15-3 in its usage in management of patients with breast cancer.

### Limitations:

These services are not covered for the evaluation of patients with signs or symptoms suggestive of malignancy. The service may be ordered at times necessary to assess either the presence of recurrent disease or the patient's response to treatment with subsequent treatment cycles.

### Most Common Diagnoses (which meet medical necessity) \*

C50.011 through C50.929	All malignant neoplasm of breast diagnosis codes
C79.81	Secondary malignant neoplasm of breast
G89.3	Neoplasm related pain
R97.8	Other abnormal tumor markers
Z85.3	Personal history of malignant neoplasm of breast

\*For the full list of diagnoses that meet medical necessity see the Tumor Antigen by Immunoassay 15-3 /CA 27.29 National Coverage Determination 190.29 document.

The above CMS and WPS-GHA guidelines are current as of: 4/01/2024.